Upstream Bio, Inc. (NASDAQ:UPB) Stock Rated “Hold” by Sell-Side Brokerages

Upstream Bio, Inc. (NASDAQ:UPB) has earned a consensus rating of “Hold” from the seven brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $29.67.

A number of equities analysts have issued reports on UPB shares. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of Upstream Bio in a research note on Wednesday, September 2nd. Truist Financial lowered their price objective on Upstream Bio to $25.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Weiss Ratings raised Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 17th. Wall Street Zen lowered Upstream Bio from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, JPMorgan Chase & Co. lifted their target price on Upstream Bio from $8.00 to $9.00 and gave the company a “neutral” rating in a research report on Friday, August 14th.

Institutional Investors Weigh In On Upstream Bio

Institutional investors and hedge funds have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio purchased a new stake in shares of Upstream Bio in the second quarter valued at about $33,000. Persistent Asset Partners Ltd bought a new position in shares of Upstream Bio during the second quarter valued at about $34,000. The Manufacturers Life Insurance Company lifted its position in shares of Upstream Bio by 51.2% during the first quarter. The Manufacturers Life Insurance Company now owns 15,338 shares of the company’s stock valued at $138,000 after purchasing an additional 5,191 shares in the last quarter. Hsbc Holdings PLC purchased a new position in Upstream Bio during the second quarter worth about $78,000. Finally, Canada Pension Plan Investment Board purchased a new position in Upstream Bio during the second quarter worth about $80,000.

Upstream Bio Price Performance

Shares of NASDAQ UPB opened at $2.76 on Wednesday. The stock has a market capitalization of $151.17 million, a P/E ratio of -0.95 and a beta of 1.38. The company has a 50-day moving average price of $5.74 and a 200-day moving average price of $7.16. Upstream Bio has a 1 year low of $2.74 and a 1 year high of $33.68.

Upstream Bio (NASDAQ:UPB) last posted its earnings results on Tuesday, August 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.01. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. The company had revenue of $0.77 million during the quarter, compared to the consensus estimate of $0.56 million. As a group, equities research analysts anticipate that Upstream Bio will post -2.84 earnings per share for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases. The company’s research is centered on targeting biological pathways involved in immune-system activation and chronic inflammation, with an emphasis on conditions affecting the airways.

Upstream Bio’s lead product candidate is verekitug, formerly known as UPB-101. Verekitug is a long-acting monoclonal antibody designed to selectively inhibit thymic stromal lymphopoietin, or TSLP, a cytokine that contributes to the development and persistence of inflammation.